Brainstorm Cell Therapeutics Stock Performance
| BCLI Stock | USD 1.74 0.12 7.41% |
The firm shows a Beta (market volatility) of -1.07, which signifies a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Brainstorm Cell are expected to decrease slowly. On the other hand, during market turmoil, Brainstorm Cell is expected to outperform it slightly. At this point, Brainstorm Cell Ther has a negative expected return of -1.26%. Please make sure to confirm Brainstorm Cell's standard deviation, kurtosis, period momentum indicator, as well as the relationship between the maximum drawdown and day median price , to decide if Brainstorm Cell Ther performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Brainstorm Cell Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in December 2024. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor 1:15 | Last Split Date 2024-10-01 |
1 | Acquisition by Uri Yablonka of 13333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3 | 09/16/2024 |
2 | Brainstorm Cell Therapeutics Research Coverage Started at StockNews.com | 09/27/2024 |
3 | Acquisition by Chaim Lebovits of 22000 shares of Brainstorm Cell at 0.228 subject to Rule 16b-3 | 09/30/2024 |
4 | Acquisition by Chaim Lebovits of 1836 shares of Brainstorm Cell at 3.4272 subject to Rule 16b-3 | 10/01/2024 |
5 | Brainstorm cell therapeutics CEO acquires 11,308 in stock | 10/02/2024 |
6 | Disposition of 9600 shares by Patlis Alla of Brainstorm Cell at 9.51 subject to Rule 16b-3 | 10/10/2024 |
7 | Acquisition by Chaim Lebovits of 135000 shares of Brainstorm Cell at 0.3753 subject to Rule 16b-3 | 10/11/2024 |
8 | BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn Expanded Access Program at 2024 Annual NEALS Meeting | 10/28/2024 |
9 | Acquisition by Arbel Irit of 25333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3 | 11/12/2024 |
| Begin Period Cash Flow | 772 K |
Brainstorm |
Brainstorm Cell Relative Risk vs. Return Landscape
If you would invest 438.00 in Brainstorm Cell Therapeutics on September 1, 2024 and sell it today you would lose (264.00) from holding Brainstorm Cell Therapeutics or give up 60.27% of portfolio value over 90 days. Brainstorm Cell Therapeutics is currently does not generate positive expected returns and assumes 6.157% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of stocks are less volatile than Brainstorm, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Brainstorm Cell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Brainstorm Cell's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Brainstorm Cell Therapeutics, and traders can use it to determine the average amount a Brainstorm Cell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2054
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BCLI |
Estimated Market Risk
| 6.16 actual daily | 54 54% of assets are less volatile |
Expected Return
| -1.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Brainstorm Cell is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Brainstorm Cell by adding Brainstorm Cell to a well-diversified portfolio.
Brainstorm Cell Fundamentals Growth
Brainstorm Stock prices reflect investors' perceptions of the future prospects and financial health of Brainstorm Cell, and Brainstorm Cell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Brainstorm Stock performance.
| Return On Equity | -11.22 | ||||
| Return On Asset | -1.78 | ||||
| Current Valuation | 10.6 M | ||||
| Shares Outstanding | 5.7 M | ||||
| Price To Earning | (16.00) X | ||||
| Price To Book | 65.82 X | ||||
| EBITDA | (16.93 M) | ||||
| Net Income | (17.19 M) | ||||
| Cash And Equivalents | 12.24 M | ||||
| Cash Per Share | 0.34 X | ||||
| Total Debt | 672 K | ||||
| Debt To Equity | 0.60 % | ||||
| Current Ratio | 1.63 X | ||||
| Book Value Per Share | (1.21) X | ||||
| Cash Flow From Operations | (20.46 M) | ||||
| Earnings Per Share | (3.45) X | ||||
| Market Capitalization | 9.92 M | ||||
| Total Asset | 4.21 M | ||||
| Retained Earnings | (215.01 M) | ||||
| Working Capital | (5.69 M) | ||||
| Current Asset | 16.79 M | ||||
| Current Liabilities | 2.95 M | ||||
About Brainstorm Cell Performance
By evaluating Brainstorm Cell's fundamental ratios, stakeholders can gain valuable insights into Brainstorm Cell's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Brainstorm Cell has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Brainstorm Cell has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.09) | (4.29) | |
| Return On Capital Employed | 5.97 | 6.27 | |
| Return On Assets | (4.09) | (4.29) | |
| Return On Equity | 3.54 | 3.72 |
Things to note about Brainstorm Cell Ther performance evaluation
Checking the ongoing alerts about Brainstorm Cell for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Brainstorm Cell Ther help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Brainstorm Cell Ther generated a negative expected return over the last 90 days | |
| Brainstorm Cell Ther has high historical volatility and very poor performance | |
| Brainstorm Cell Ther may become a speculative penny stock | |
| Brainstorm Cell Ther has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (17.19 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Brainstorm Cell Therapeutics currently holds about 12.24 M in cash with (20.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34. | |
| Brainstorm Cell Ther has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Arbel Irit of 25333 shares of Brainstorm Cell at 0.75 subject to Rule 16b-3 |
- Analyzing Brainstorm Cell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Brainstorm Cell's stock is overvalued or undervalued compared to its peers.
- Examining Brainstorm Cell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Brainstorm Cell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Brainstorm Cell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Brainstorm Cell's stock. These opinions can provide insight into Brainstorm Cell's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Brainstorm Stock analysis
When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |